Quick Answer
Arcturus Therapeutics Holdings Inc. reported Revenue (ASC 606) of $82.03 million for fiscal year 2025.
Arcturus Therapeutics Holdings Inc. Revenue (ASC 606) — Annual History
| Fiscal Year | Revenue (ASC 606) | YoY Change |
|---|---|---|
| 2025 | $82.03M | -46.1% |
| 2024 | $152.31M | -8.7% |
| 2023 | $166.80M | -19.0% |
| 2022 | $206.00M | +1566.8% |
| 2021 | $12.36M | +29.6% |
| 2020 | $9.54M | -54.1% |
| 2019 | $20.79M | +32.0% |
| 2018 | $15.75M | — |
Quarterly Revenue (ASC 606)
| Quarter Ending | Revenue (ASC 606) | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $17.15M | -58.8% | -39.4% |
| June 30, 2025 | $28.30M | -43.2% | -3.7% |
| March 31, 2025 | $29.38M | -22.7% | -29.5% |
| September 30, 2024 | $41.67M | -7.7% | -16.4% |
| June 30, 2024 | $49.86M | +374.0% | +31.2% |
| March 31, 2024 | $38.01M | -52.7% | -15.8% |
| September 30, 2023 | $45.14M | +237.6% | +329.1% |
| June 30, 2023 | $10.52M | -61.2% | -86.9% |
- Arcturus Therapeutics Holdings Inc. showed a decrease of -46.1% in Revenue (ASC 606) compared to the prior fiscal year.
- Over the 2018–2025 period, Arcturus Therapeutics Holdings Inc.’s revenue (asc 606) has grown by 420.7% (from $15.75 million to $82.03 million).
- The most recent figure is from Arcturus Therapeutics Holdings Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 3, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: